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Cell survivalRenal cell carcinoma is a common neoplasia of the adult kidney that accounts for about 3% of adult
malignancies. Clear cell renal carcinoma is the most frequent subtype of kidney cancer and 20–40%
of patients develop metastases. The absence of appropriate biomarkers complicates diagnosis and
prognosis of this disease. In this regard, small noncoding RNAs (microRNAs), which are mutated
in several neoplastic diseases including kidney carcinoma, may be optimal candidates as biomarkers
for diagnosis and prognosis of this kind of cancer. Here we show that patients with clear cell kidney
carcinoma that express low levels of miR501-5p exhibited a good prognosis compared with patients
with unchanged or high levels of this microRNA. Consistently, in kidney carcinoma cells the down-
regulation of miR501-5p induced an increased caspase-3 activity, p53 expression as well as
decreased mTOR activation, leading to stimulation of the apoptotic pathway. Conversely, miR501-
5p upregulation enhanced the activity of mTOR and promoted both cell proliferation and survival.
These biological processes occurred through p53 inactivation by proteasome degradation in a mech-
anism involving MDM2-mediated p53 ubiquitination. Our results support a role for miR501-5p in
balancing apoptosis and cell survival in clear cell renal carcinoma. In particular, the downregulation
of microRNA501-5p promotes a good prognosis, while its upregulation contributes to a poor prog-
nosis, in particular, if associated with p53 and MDM2 overexpression andmTOR activation. Thus, the
expression of miR501-5p is a possible biomarker for the prognosis of clear cell renal carcinoma.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Renal cell carcinoma (RCC), the most common kidney malig-
nancy with the highest mortality rate of urinary cancers, shows
an incidence of 2–4% in the USA population that is steadily rising
in the last decades [9,33]. Clear cell renal carcinoma (ccRCC)
accounts for about 70% of RCC cases and, approximately one thirdof these patients commonly develop metastases [10]. Tumor recur-
rence manifestations are mainly due to the absence of adjuvant
therapy in clinical routine, because RCC is both chemotherapy
and radiotherapy resistant [31]. Moreover, the lack of speciﬁc
prognostic biomarkers prevents the development of speciﬁc ther-
apy. Thus, the discovery of new biomarkers for the prediction of
early metastasis development after nephrectomy could be useful
for the clinic and therapeutic follow up of RCC patients [31,35].
Currently, an innovative approach for molecular characterization
of tumors is based on the analysis of microRNAs expression [31].
MicroRNAs (miRs) are a class of short non-coding RNAs that
regulate gene expression at post-transcriptional level by mRNA
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been reported as potential biomarkers for RCC, because they are
able to improve the identiﬁcation of tumor subtypes [29]. For
instance, the overexpression of miR-32 is associated with poor out-
come of RCC patients [29]. However, in other studies the analysis of
circulating serum levels of miR-26a-2⁄, miR-191, miR-337-3p and
miR-378 is unlikely to provide helpful diagnostic/prognostic infor-
mation in RCC patients [16]. Therefore, the current role of miRs as
biomarkers in renal carcinoma is still obscure and deserves further
investigation.
In the RCC pathogenesis it is known that mTOR, a protein kinase
essential for cell growth, has an important role, because increased
mTORC1 activation by the HIF2a pathway is particularly associ-
ated to renal cancer progression [14]. Moreover, genetic mutations
that enhance mTOR signaling cause increased incidence of meta-
static events [19]. Consistently, inhibitors of mTOR have shown
to improve survival in poor-prognosis advanced RCC [19,15].
Therefore, also mTOR signaling should be carefully investigated
in kidney tumors.
The ﬁndings here reported show that low expression level of a
speciﬁc miR, the miR501-5p, does not affect tumor grading, but is
associated with a good prognosis in ccRCC patients. Moreover, the
downregulation of miR501-5p induces apoptosis through p53 acti-
vation and mTOR inhibition. Consistently, the overexpression of
miR501-5p in kidney carcinoma KJ29 cells stimulates cell growth
and survival by activation of mTOR kinase and inhibition of p53
via MDM2-associated ubiquitination. The good prognosis in ccRCC
patients associated with lower expression of miR501-5p makes
this miR a candidate biomarker for clear cell renal carcinoma.2. Material and methods
2.1. Reagents
Media and plastic material for cell culture were purchased from
EuroClone (Italy). Rabbit polyclonal anti-mTOR, anti-P-mTOR, and
anti-Ubiquitin antibodies were obtained from Cell Signaling Tech-
nologies (EuroClone, Italy). Anti-p53, anti-MDM2 and anti-b-Actin
were acquired from Santa Cruz Technologies (Italy). Enhanced
chemiluminescent substrates for western blotting and HRP-conju-
gated goat anti-rabbit and anti-mouse antibodies were purchased
from EuroClone (Italy). Rapamycin was obtained from Sigma–
Aldrich (Italy). AntagomiR anti-microRNA501-5p was purchased
by Ambion (Life Technologies, Italy), while the recombinant plas-
mid (PL501) expressing both hsa-miR501-5p and green ﬂuores-
cence protein (GFP) sequences was produced by OriGene
Technologies (Tema Ricerca, Italy).
2.2. Collection of sample tissues and kidney cell lines
Renal fresh frozen normal and tumor kidney tissues were col-
lected after surgical resection by the Urology Unit of Sant’Anna
Hospital, Ferrara. Parafﬁn-embedded tissues derived from normal
parenchyma as well as from kidney renal carcinoma were obtained
from Pathological Anatomy of Ferrara University (Italy). 4/5 human
normal as well as 9.7 and 9.12 ADPKD cystic kidney epithelial cells
were produced by other laboratories [20], while KJ29 non papillary
kidney cancer cells were established and characterized in our lab-
oratory [5]. Cytogenetic analysis of KJ29 cells showed 50 chromo-
somes including rearrangements of chromosomes 1 and 3. The
antigenic phenotype is characterized by co-expression of cytoker-
atin and vimentin as well as the expression of urothelium differen-
tiation markers, with low levels of class II and the absence of class I
MHC antigens. The cell line which is highly tumorigenic in athymic
mice displays expression of erbB-2, c-met and Ha-ras oncogenes[5]. Caki-2 cells were kindly provided from Dr. Gagliano (Univer-
sity of Milan, Italy). The study protocol was in line with the 1975
Declaration of Helsinki.
2.3. Analysis of microRNA expression by microarray technology
This analysis was performed as described by Negrini et al. [24].
Brieﬂy, after total RNA isolation from cells by TRIZOL reagent (Invit-
rogen SRL, Italy) as already described [21], RNAswere hybridized on
an Agilent Human miRNA microarray (G4470B, Agilent Technolo-
gies), which consists of 60-mer DNA probes synthesized in situ
and contains 15,000 features speciﬁc for 723humanmiRNAs.Micro-
array results were analyzed using the GeneSpring GX software (Agi-
lent Technologies). Differentially expressedmiRNAwere selected as
having a 1.5-fold expression difference between control cells (4/5)
and ADPKD cystic cells (9.7 and 9.12). P values <0.05 calculated by
Anova test was considered statistically signiﬁcant. Differentially
expressed miRNAs were used for cluster analysis of samples, using
the Pearson correlation as a measure of similarity.
2.4. RNA extraction, cDNA synthesis and RT-PCR analysis
From fresh frozen tissues and cell pellets, total RNA was
extracted by TRIZOL method. RNA extraction from parafﬁn-embed-
ded tissues was performed by the RecoverAll Total Nucleic Acid
Isolation Kit (Ambion, Italy). Four slices from 20 lm in size were
treated with 1 mL of xylene 100% and heated for 3 min a 50 C to
melt the parafﬁn, and the solution was centrifuged at 12000g
for 2 min. After xylene discharge, the pellet was washed twice with
1 mL 100% ethanol and dried in a centrifugal vacuum at 40 C for
20 min. Next, RNA from samples were obtained following the man-
ufacturer’s protocol. Synthesis of cDNA was performed by the Taq-
Man MicroRNA Reverse Transcription Kit (Applied Biosystems,
Italy), using RNU6B and hsa-miR501-5p speciﬁc primers. Real Time
quantitative PCR was carried out by TaqMan method using the ABI
Prism 7700 Sequencer Detector system (Applied Biosystems, Italy).
The small nuclear U6B was used as endogenous control (reference
gene) for the normalization of samples, while the expression level
of microRNA501-5p between normal parenchyma and cancer tis-
sue was calculated by delta-delta Ct method as previously
described [4].
2.5. Cell transfection
The transfection of cells with 30 nM of antagomiR sequences,
speciﬁc for microRNA501-5p or with 0.75 lg/mL of PL501 was per-
formed by the TurboFect Transfection Reagent (Fermentas, Italy).
200,000, 30,000 or 5000 cells/well were plated in 6-, 24- or 96-well
plates respectively, for 24 h in DMEM/F12 medium supplemented
with 10% FBS. Next, cells were transiently transfected in DMEM/
F12 medium supplemented with 0.4% BSA for at least 6 h following
the manufacturer’s method. After transfection cells were cultured
for 24 h in DMEM/F12 medium in presence of 0.4% BSA for the
analysis of apoptosis or for 24, 48 and 72 h in 1% FBS for the eval-
uation of cell growth.
2.6. Analysis of cell cycle, proliferation and survival
For cell cycle analysis, 200,000 cells/well were plated in six well
plates, starved for 24 h in medium with 0.4% BSA, transfected with
a speciﬁc antagomiR and cultured for additional 24 h in medium
containing 1% FBS. Then, cells were collected, centrifuged, washed
in PBS, stained with a propidium iodide solution and analyzed by
ﬂow cytometry using the FACSCalibur Becton Dickinson Immuno-
cytometry System [1]. For cell proliferation analysis, 5000 cells/
well were plated in 96 well plates, starved for 24 h in DMEM/F12
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as described above. Cells were cultured for further 24, 48 and 72 h
in DMEM/F12 1% FBS in presence or absence of rapamycin
(500 nM), and the proliferation was calculated by direct cell count-
ing after trypan blue staining, using a Burker chamber [3]. Cell sur-
vival was measured by the CellTiter cell proliferation assay
(Promega, Italy), a method based on the quantitation of a colored
compound released by cells in culture medium. Color intensity,
directly proportional to the living cells, was detected by a plate
reader recording the absorbance at 490 nm [8].
2.7. Western blotting and p53-ubiquitination analysis
Fresh tissues were lysed in 1% Triton X-100 solution containing
a cocktail of protease inhibitors and processed for immunoblots as
described previously [2]. Quantitative phosphorylation and protein
levels were calculated as the ratio between phosphorylated and
un-phosphorylated protein, and among the protein of interest
and b-Actin, respectively [3]. For detection of p53 conjugated with
endogenous ubiquitin, transfected cells (1  106) were lysed in TBS
buffer (50 mM Tris, pH 8.0, 150 mM NaCl) containing 1% SDS,
1 mM DTT and protease inhibitor cocktail enriched with protea-
some and ubiquitin peptidase inhibitors MG132 (10 lm) and N-
ethylmaleimide (10 mM), respectively. Next, protein lysate was
boiled and diluted 10 times in TBS with protease inhibitors, and
p53 was immunoprecipitated with a monoclonal anti-p53 anti-
body (Santa Cruz, Italy). After washing, immunoprecipitates were
analyzed by western blotting with both monoclonal anti-p53 and
polyclonal anti-Ubiquitin antibodies [26].
2.8. Apoptosis detection
Apoptosis was evaluated by Hoechst and caspase-3 assay meth-
ods. For apoptotic nuclei detection, 200,000 cells were plated on
24 mm coverslips, starved 24 h in DMEM/F12 0.4% BSA and trans-
fected. After transfection, cells were ﬁxed, permeabilized, and
stained with Hoechst 33,258 (10 mg/mL) in the dark [8]. Images
were acquired at 40 magniﬁcation through a Zeiss Axiovert 200
ﬂuorescence microscope, equipped with a back-illuminated CCD
camera (Roper Scientiﬁc, Tucson, USA). Caspase-3 activity was
evaluated using EnzChek caspase-3 Assay Kit (Invitrogen, Italy).
After transfection, cells were cultured with DMEM/F12 0.4% BSA
for 24 h, lysed for 30 min and centrifuged according with the man-
ufacturer’s instructions. 50 lL aliquots of supernatant were incu-
bated with 50 lL of 2 substrate working solution containing
5 mM Z-DEVD-R110 and ﬂuorescence was measured every minute
for 90 min at 520 nm by the ﬂuorimeter VICTOR3 1420 Multilabel
Counter (PerkinElmer, Italy). Values were normalized to the pro-
tein content detected by Bradford method [8].
2.9. Cell imaging
For GFP detection, cells were seeded on 24 mm coverslips,
transfected with PL501 and washed three times with PBS buffer
before GFP recording. GFP ﬂuorescence signal was captured by a
ﬂuorescence microscope as described above. For immunoﬂuores-
cence analysis, cells were cultured on 24 mm coverslips in
DMEM/F12 0.4% BSA for 24 h and transfected with antagomiR.
After transfection, cells were ﬁxed in 0.4% formalin, washed twice
in PBS buffer and permeabilized in a PBS solution containing 0.2%
Triton X-100. Then, cells were washed twice with PBS buffer and
incubated with an anti-p53 monoclonal antibody solution. After
washing, cells were treated with a secondary anti-mouse rhoda-
mine-conjugated antibody and washed three times in PBS buffer
[4]. Immunoﬂuorescent p53 protein and DAPI-stained nuclei were
detected by a ﬂuorescence microscope as previously described.2.10. Statistical analysis
Analysis of data was performed using Student’s t test (unpaired
analysis). Patients survival was measured by Kaplan–Meier estima-
tor and by multivariate analysis with Cox regression. Statistical
analysis of microarray data was performed by Anova test. Differ-
ences are considered signiﬁcant at a value of p < 0.05. All data
are reported as mean ± SD (standard deviation) of at least three
independent experiments.
3. Results
3.1. miR501-5p expression in kidney carcinomas
Microarray data performed in 4/5 normal renal epithelial cells
as well as in 9.7 and 9.12 cystic kidney cell lines [20] derived from
patients with autosomal dominant polycystic kidney disease
(ADPKD), an hyperproliferative pathology, showed statistically sig-
niﬁcant changes in the expression of six different microRNAs
(Fig. 1A). In particular the expression of microRNA501-5p was
found 3 times higher in 9.7 and 9.12 cystic cells than in 4/5 control
cells (Table in Fig. 1A). By Real Time RT-PCR analysis, an overall
higher expression of miR501-5p was also observed in 63 clear cell
kidney carcinoma tissues compared with their paired normal renal
parenchyma (Fig. 1B), while the other miRNAs did not show signif-
icant changes (data not shown). On the contrary, in 19 papillary
kidney carcinoma tissues the expression of this miR was markedly
lower than in normal tissue (Fig. 1C). As shown in Fig. 1D, ccRCC
samples showed a variable distribution of miR501-5p expression
that could be associated with age, because this correlation is very
close to signiﬁcance. No association between miR-501-5p expres-
sion and tumor grade was observed (Fig. 1E). Based on this variable
distribution, a possible link between miR501-5p expression and
patient outcome in ccRCC subjects was then investigated. Follow
up analysis (at least 5 years) in 45 ccRCC samples (Table 1) showed
that patients with low expression of this miR (<1; tumor vs normal
tissue) exhibited a good prognosis. Conversely, 66% of patients
with higher levels of miR501-5p (P1; tumor vs normal tissue)
showed a signiﬁcant higher probability of developing metastases
than subjects with low expression of this miR; (miR501-5p expres-
sion was 5.34 ± 7.31 in metastatic samples vs 1.73 ± 2.47 in not-
metastatic ccRCC patients; n = 45, p < 0.05). This ﬁnding was also
conﬁrmed by Kaplan–Meier plot that indicates a signiﬁcant lower
frequency of metastases for patients which express low levels of
microRNA501-5p compared with subjects with high expression
of this microRNA (Fig. 1F). However, Kaplan–Meier chart did not
show signiﬁcant association with the overall survival (data not
shown). In addition, a multivariable Cox regression analysis was
performed on ccRCC patients stratiﬁed for age in two groups
(<65 years (n = 10) deﬁned ‘‘young’’ and >65 (n = 27) called
‘‘old’’). This analysis indicates that expression of miR501-5p
showed a signiﬁcant and independent association with time to
metastasis (HR 1.103; 95%CI 1.004–1.211, p < 0.05).
These data suggest a possible role of miR501-5p in the develop-
ment of clear cell renal carcinoma.
3.2. The upregulation of miR501-5p stimulates cell growth and
survival
Since TSC1, an inhibitor component of mTOR complex [37], is a
target of miR501-5p (Table 2), the upregulation of this miR should
activate the mTOR kinase. To conﬁrm this assumption, we have
overexpressed the miR501-5p in two different kidney carcinoma
cell lines (KJ29 and Caki-2), by transfection with a plasmid
(PL501) containing speciﬁc miR501-5p sequences. In basal condi-
tions (Fig. 2A), miR501-5p levels were higher in KJ29 cells than
Fig. 1. miR501-5p expression in kidney carcinomas. (A) Map of cluster analysis in normal kidney epithelial cells (4/5) and in two different ADPKD cystic cell lines (9.7 and
9.12) performed by microarray technology showed changes in the expression of six different microRNAs. Expression values and statistical signiﬁcance of different miRNAs
(calculated as fold change ratio between ADPKD cystic cells vs normal kidney cells), were indicated in the table. Levels of miR501-5p were analyzed by Real Time RT-PCR in 63
pairs of ccRCC and normal kidney tissues (B) and, in 19 pairs of pRCC and normal kidney parenchyma (C) of patients from Northern Italy. Data from fresh frozen and parafﬁn
embedded tissues were pooled together because miR501-5p values obtained from both samples were comparable. Real Time RT-PCR values, expressed as ratio between
cancer tissues and normal kidney parenchyma, were calculated by delta-delta Ct method. In ccRCC tissues the expression of miR501-5p was 2.76 ± 4.86-fold increased
compared with control tissues (⁄⁄p < 0.01). In pRCC tissues miR501-5p expression with respect to normal tissue was 0.56 ± 0.87 (⁄p < 0.05). (D) Pearson analysis showed a
weakly positive, albeit not signiﬁcant, correlation between miR501-5p expression and age of patients (p = 0.0519). (E) No association between miR501-5p expression and
tumor grade, as evaluated by t-test, was observed. (F) Kaplan–Meier plot indicated a lower frequency of metastatic events in ccRCC patients with low expression of miR501-
5p compared with those expressing greater levels of this microRNA. Kaplan–Meier estimator was performed by using as cut off the median expression of miR501-5p;
median = 1.24 (tumors vs normal tissue). Statistical analysis of miR501-5p expression was performed by t-test in three experiments in duplicate. Values are shown as
mean ± standard deviation. Control = normal kidney parenchyma (1 expression level); ccRCC = clear cell renal cell carcinoma; pRCC = papillary renal cell carcinoma;
G = tumor grading (Fuhrman scale).
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increased the expression of miR501-5p in both KJ29 and Caki-2
kidney carcinoma cells (Fig. 2B and 2C). Because cell detachment
might occur after transfection with 1.5 lg/mL of PL501, we per-
formed further experiments with 0.75 lg/mL or less. As we specu-
lated, the increased expression of miR501-5p increased the
phosphorylation of mTOR kinase in PL501-transfected KJ29 cells
(Fig. 2D). Consistently, similar data were obtained by using Caki-
2 cells (Fig. 2E). Since mTOR signaling stimulates several biological
processes including cell proliferation and survival [34], the upreg-
ulation of miR501-5p in both KJ29 and Caki-2 PL501-transfected
cells was associated with signiﬁcantly increased cell proliferation
and survival (Fig. 2F–H). Transfection with lower doses of PL501
(<0.75 lg/mL) still enhanced cell growth and survival, even if with
milder effects (data not shown). Interestingly, mTOR signaling is
known to stimulate MDM2 expression [23,13], an inhibitor of the
oncosuppressor p53 in metastatic kidney cancer [25]. Therefore,
the upregulation of miR501-5p that stimulates mTOR, should also
affect the expression of MDM2 and p53 proteins. As expected, the
transfection of KJ29 and Caki-2 cells with PL501 not only caused an
enhanced expression of MDM2, but also induced a signiﬁcantreduction of p53 levels (Fig. 3A and B). MDM2 is an E3 ubiquitin-
protein ligase that on interacting with p53 causes polyubiquitina-
tion and degradation of MDM2/p53 complex by proteasome acti-
vation [30]. Consistently, in KJ29 cells overexpressing miR501-5p
sequences an increased p53 protein ubiquitination was detected
(Fig. 3C). Pharmacological inhibition of mTOR activity by rapamy-
cin treatment of KJ29 cells transfected with PL501 (Fig. 3D) raised
the levels of p53 protein by inhibition of MDM2 expression
(Fig. 3D). Moreover, the treatment with 500 nM rapamycin in
PL501-transfected cells also caused a signiﬁcant reduction of cell
proliferation and survival compared with untreated cells
(Fig. 3E–G). These data suggest that miR501-5p, likely through
TSC1 mRNA degradation, stimulates cell proliferation and survival
by degradation of p53 in a mechanism involving the activation of
mTOR kinase and MDM2 expression in kidney carcinoma cells.
3.3. MicroRNA501-5p downregulation induces cell death by activation
of apoptotic machinery
Since the upregulation of miR501-5p stimulates cell prolifera-
tion and survival, it is presumable that its reduction may be asso-
Table 1
Follow-up analysis shows that miR501-5p downregulation is associated with a good prognosis in clear cell renal carcinoma patients.
Samples Age Grading Metastasis miR501-5p Therapy Outcome
ccRCC1 89 G2 No 0.15 No Dead
ccRCC2 85 G2 No 0.17 No Alive
ccRCC3 61 G2 No 0.2 No Alive
ccRCC4 70 G2 No 0.22 No Alive
ccRCC5 76 G2 No 0.28 No Alive
ccRCC6 60 G2 No 0.3 No Alive
ccRCC7 78 G2 No 0.31 No Alive
ccRCC8 73 G1 No 0.32 No Alive
ccRCC9 76 G2 No 0.35 No Alive
ccRCC10 73 G3 No 0.51 No Alive
ccRCC11 46 G3 No 0.58 No Alive
ccRCC12 54 G2 No 0.81 No Alive
ccRCC13 56 G1 No 0.82 No Alive
ccRCC14 82 G2 No 0.82 No Alive
ccRCC15 76 G4 Lung 0.97 ND Dead
ccRCC16 67 G2 No 1.02 No Alive
ccRCC17 53 G3 Brain/lung 1.03 Anti-VEGFR Dead
ccRCC18 86 G2 Lung 1.05 Anti-VEGFR Alive
ccRCC19 68 G1 No 1.08 No Alive
ccRCC20 73 G3 No 1.17 No Alive
ccRCC21 59 G3 Kidney 1.22 ND Alive
ccRCC22 62 G2 No 1.24 No Alive
ccRCC23 69 G4 Lung/liver 1.3 ND Dead
ccRCC24 79 G3 Lung/liver 1.31 No Alive
ccRCC25 70 G2 Lung 1.41 Anti-VEGFR Alive
ccRCC26 64 G4 Bones/liver 1.43 No Dead
ccRCC27 60 G3 Liver 1.48 Anti-VEGFR Alive
ccRCC28 48 G2 No 1.62 No Alive
ccRCC29 71 G3 Bones 1.86 ND Dead
ccRCC30 73 G2 No 2.03 No Alive
ccRCC31 44 G2 No 2.06 No Alive
ccRCC32 78 G3 No 4.06 No Alive
ccRCC33 86 G2 Larynx/urothelium 4.53 ND Dead
ccRCC34 69 G2 Bones 4.58 ND Alive
ccRCC35 67 G3 Brain/liver/lung 4.77 Anti VEGFR Dead
ccRCC36 66 G3 Lung/liver 5.24 Anti-VEGFR Alive
ccRCC37 74 G3 Liver 5.49 ND Dead
ccRCC38 75 G2 No 5.86 No Alive
ccRCC39 50 G2 Lung/bones 6.16 Anti-VEGFR Alive
ccRCC40 83 G2 Lymph nodes 7.17 No Dead
ccRCC41 81 G2 No 8.59 No Dead
ccRCC42 83 G3 Lung/bones 8.7 Anti-VEGFR Dead
ccRCC43 73 G2 No 8.82 No Alive
ccRCC44 35 G1 Lung 14.36 ND Alive
ccRCC45 87 G3 Bones 32.81 ND Dead
For follow-up studies, 45 ccRCC patients with at least 5 years from surgical resection were considered. Biological and clinical parameters matched with miR501-5p expression
are indicated.
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apoptosis. To evaluate this hypothesis the expression of miR501-
5p in KJ29 and Caki-2 kidney carcinoma cells was reduced by
transfection with a speciﬁc antagomiR. As expected, this transfec-
tion caused a marked reduction of miR501-5p expression as com-
pared to cells transfected with scramble sequences (Fig. 4A).
Moreover, the decreased expression of miR501-5p in these cells
induced a signiﬁcant reduction of cell survival (Fig. 4B and C) as
well as a cell accumulation in G0/G1 phase of cell cycle in KJ29 cells
treated with antagomiR, as compared to same cells transfected
with scramble sequences (Fig. 4D). Furthermore, an activation of
caspase-3, the last enzyme of caspase cascade triggering the apop-
totic pathway, was also observed (Fig. 4E). Consistently, in antago-
miR-transfected KJ29 cells the formation of apoptotic nuclei, not
detected in control cells, was shown (Fig. 5A). Therefore, the
decrease of miR501-5p expression stimulates apoptotic activity
in kidney carcinoma cells. As previously shown, the upregulation
of miR501-5p stimulated the activity of mTOR in KJ29 and Caki-2
cells, therefore, it is reasonable to think that the reduction of this
microRNA may affect the mTOR signaling reducing the activity of
this protein kinase. Actually, the downregulation of miR501-5p inboth KJ29 and Caki-2 cells transfected with antagomiR induced a
marked reduction of mTOR protein phosphorylation compared
with cells transfected with scramble sequences (Fig. 5B). Further-
more, the decreased activity of mTOR in these cells caused a signif-
icant reduction in the expression of MDM2 protein (Fig. 5C) that in
turn induced a rising of p53 levels, not detected in control cells
(Fig. 6A and B). In particular, antagomiR-transfected KJ29 cells also
showed a most p53 nuclear translocation (Fig. 6C) compared with
KJ29 control cells, where p53-staining was mainly conﬁned to the
cytoplasm (Fig. 6C).
These results suggest that miR501-5p downregulation in KJ29
kidney carcinoma cells activates apoptosis by increased expression
and function of p53 and inhibition of both mTOR activity and
MDM2 expression.
3.4. Role of miR501-5p expression in clear cell kidney carcinoma
tissues
As observed in KJ29 kidney carcinoma cells, also in ccRCC tis-
sues the low expression of miR501-5p (<1 vs normal parenchyma)
was associated with higher expression of the tumor suppressor
Table 2
Putative gene targets of miR501-5p involved in cell proliferation and apoptosis.
Gene Name Function Biological processes
TSC1 Tuberous sclerosis 1 Tumor suppressor mTOR signaling
Casp1 Apoptosis-related cysteine peptidase Caspase cascade Apoptosis
Casp2 Apoptosis-related cysteine peptidase Caspase cascade Apoptosis
Casp8 Apoptosis-related cysteine peptidase Caspase cascade Apoptosis
Fas Cell surface death receptor TNF receptor superfamily Apoptosis
GAS2 Growth arrest-speciﬁc 2 Caspase-3 substrate Apoptosis
CARD16 Caspase recruitment domain family, member 1 Caspase activator Apoptosis
BLID BH3-like motif containing, cell death inducer Caspase activator Pro apoptotic
BCL2L11 BCL2-Like 11 (Apoptosis Facilitator) Bcl-2 family proteins Pro apoptotic
ING3 Inhibitor of growth family, member 3 Tumor suppressor Apoptosis
MCU Mitochondrial calcium uniporter Calcium channel Apoptosis
PTEN Phosphatase and tensin Tumor suppressor Apoptosis
DCC Deleted in colorectal carcinoma Tumor suppressor Apoptosis
MTSS1 Metastasis suppressor 1 Tumor suppressor Cell migration inhibition
BRCA1 Breast cancer 1, early onset Tumor suppressor DNA damage repair
Rictor Rapamycin-insensitive companion of mTOR Subunit of mTORC2 Cell growth
MAPK6 Mitogen-activated protein kinase 6 Protein kinase Cell proliferation, differentiation and development
MAP2K1 Mitogen-activated protein kinase kinase 1 Protein kinase Cell proliferation, differentiation and development
JUN Jun proto-oncogene Oncogene Gene expression regulation, tumorigenesis
KRAS Kirsten rat sarcoma viral oncogene homolog Oncogene Tumorigenesis
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog Oncogene Tumorigenesis
MYB V-myb avian myeloblastosis viral oncogene homolog Oncogene Tumorigenesis
EGFR Epidermal growth factor receptor Protein tyrosine kinase Gene expression regulation, cell proliferation
Molecular targets of miR501-5p were identiﬁed by using TargetScan Human 6.0, miRBas, miRNAMap, Miranda and DIANA-MICROT programs. Gene names, functions and
involved biological processes are indicated.
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Moreover, in these tissues a signiﬁcant reduction of MDM2 expres-
sion as well as mTOR protein phosphorylation compared with the
matched normal tissues was observed (left part of the panel in
Fig. 7A and B). Conversely, non-metastatic ccRCC samples with
high levels of microRNA501-5p (>1) with respect to normal renal
parenchyma did not show any signiﬁcant changes in p53 and
MDM2 expression or in mTOR activity compared with the paired
normal kidney tissue (right part of the panel in Fig. 7A and B). In
metastatic ccRCC tissues which usually expressed unchanged or
higher levels of this miR, a variable expression of p53 protein
was observed (Fig. 7C and D), even if in some of these metastatic
kidney cancers a tremendous expression of this protein was shown
(asterisks in Fig. 7C). However, metastatic ccRCC which express
greater levels of p53 also showed a markedly increased mTOR
activity with consequent enhanced expression of MDM2 protein
as compared to those with unchanged expression of p53 (Fig.7C
and 7E).
Taken together, these ﬁndings suggest that miR501-5p might
play an important role in clear cell kidney carcinoma favoring a
good prognosis in patients expressing low levels of this microRNA.
4. Discussion
Recent advances in understanding the molecular biology pro-
cesses of RCC is not sufﬁcient to approach a successful therapy
for this kind of cancer and patients with metastatic kidney disease
still have an extremely short life expectancy [7]. Therefore, the
research of new biomarkers able to predict possible development
of tumor metastases is a high priority not only for the prognosis
and the clinical follow up of RCC, but also for deﬁning novel ther-
apeutic strategies. In this regard, miRs, small noncoding RNAs
involved in human cancers [11] can serve as biomarkers for cancer
risk stratiﬁcation, outcome prediction and classiﬁcation of histo-
logical subtypes [31,12,17]. Differently from other cancers (lung,
colorectal carcinomas and melanoma), currently no predictive
molecular biomarkers are available for routine use in kidney carci-
noma [22].
Here, we describe miR501-5p, a non-conserved miRNA, as a
candidate biomarker for the ccRCC. In fact, the lower expressionof miR501-5p in ccRCC cancer tissues implied a better prognosis
for the patients (Table 1). Conversely, high expression levels of this
miR seems to be less accurate for prognosis prediction, even if
most of ccRCC patients with greater expression of this miR devel-
oped metastases after surgical resection (Table 1). Consistently,
clinical data processed by Kaplan–Meier test showed a signiﬁcant
correlation with the development of metastatic events in ccRCC
patients expressing high levels of microRNA501-5p compared with
those with low expression (Fig. 1F), but not a signiﬁcant associa-
tion with the overall survival (data not shown). The non-positive
correlation with patient survival, even if close to signiﬁcance
(p = 0.072), could be due to the small number of cases evaluable
in this cohort. Also data from ‘‘in vitro’’ experiments in kidney cells
showed that the overexpression of miR501-5p by PL501 transfec-
tion caused an increased cell survival in both KJ29 and Caki-2 renal
cancer cell lines (Fig. 2G and H). Similar features were also
reported for different microRNAs belonging to the same cluster
of miR501 on locus Xp 11.23, as miR532-5p, miR-500, miR362-
5p, and miR502-3p. These miRs were associated with triple-nega-
tive breast cancer proﬁle that is often related with high prolifera-
tion rate, high tumor grade and aggressive clinical behavior [18].
Moreover, the oncofetal miR500 was found overexpressed in
human hepatocellular carcinoma and could be relevant for its diag-
nosis [39]. Then, the upregulation of miR362 in gastric cancer tis-
sues induced cell proliferation and apoptosis resistance [38].
These features may be associated with the activation of mTOR sig-
naling in different cancer types including renal carcinoma [32]. In
this regard, miR501-5p should affect the activity of mTOR kinase,
because TSC1 mRNA that codiﬁes for hamartin, a component of
mTOR inhibitor [37], is a target of this miR (Table 2). Consistently,
we found that the overexpression of miR501-5p in KJ29 and Caki-2
kidney carcinoma cells increased the activation of mTOR (Fig. 2D
and E), and consequently their growth and survival. Rapamycin,
an inhibitor of mTOR, slowed indeed these biological processes
(Fig. 3E–G). Interestingly, mTOR signaling is known to positively
modulate the p53 repressor MDM2 [23,13], which is overexpressed
in advanced kidney cancer [25]. Reliably, the overexpression of
miR501-5p in both KJ29 and Caki-2 renal carcinoma cells, via the
mTOR kinase, caused a strong increase in MDM2 content and con-
sequently a marked reduction of the tumor suppressor p53 (Fig. 3A
Fig. 2. miR501-5p overexpression promoted cell growth and survival by mTOR activation. (A) Real Time RT-PCR analysis of miR501-5p shows that levels of this miR in KJ29
cells were higher than in Caki-2 cells (6.75 ± 0.64-fold increase; ⁄⁄⁄p < 0.001). KJ29 (B) and Caki-2 (C) cells were transfected for 24 h with 0.75 and 1.5 lg/mL of a recombinant
plasmid expressing both miR501-5p and GFP sequences (PL501) or with an irrelevant plasmid (control). To evaluate cell transfection efﬁciency, cells were seeded on glass
coverslips, transfected for 24 h with PL501 and acquired by a ﬂuorescence microscope at 40 magniﬁcation. Green stained cells in the boxes indicate the occurred
transfection. The expression of miR501-5p measured by Real Time RT-PCR in PL501-transfected KJ29 and Caki-2 cells was higher than in cells transfected with an irrelevant
plasmid (control). Data are expressed as fold increase ratio between PL501- and control plasmid-transfected cells. Values for KJ29 cells were: 1.82 ± 0.6 and 3.4 ± 1.2 for cells
transfected with 0.75 and 1.5 lg/mL of PL501, respectively (⁄⁄p < 0.01; ⁄⁄⁄p < 0.001). For Caki-2 cells values were: 9.2 ± 3.12 for cells transfected with 0.75 lg/mL and
26.4 ± 3.08 for those transfected with 1.5 lg/mL of PL501 plasmid (⁄⁄p < 0.01; ⁄⁄⁄p < 0.001). (D and E) The activity of mTOR kinase, analyzed by western blotting, was higher in
both PL501-transfected than in control KJ29 and Caki-2 cells. Values calculated as ratio between the phosphorylated and un-phosphorylated form of mTOR for KJ29 cells
were: 0.58 ± 0.019 for control cells and 0.89 ± 0.17 for cells transfected with 0.75 lg/mL of PL501 (⁄p < 0.05). Values for Caki-2 cells were: 0.21 ± 0.14 for control cells and
0.67 ± 0.25 for cells transfected with 0.75 lg/mL of PL501 (⁄p < 0.05). (F) Analysis of cell proliferation, performed by direct cell counting using a Burker chamber, showed an
increased cell growth in KJ29 cells transfected with PL501. Cells were transfected with 0.75 lg/mL of PL501 (KJ29–PL501) or with an irrelevant plasmid (KJ29-Control) and
cultured in DMEM/F12 supplemented with 1% FBS for 24, 48 and 72 h. After 72 h of culture the number of cells transfected with PL501 or control plasmid was 16,407 ± 2921
and 10,400 ± 350, respectively; ⁄⁄⁄p < 0.001). The upregulation of miR501-5p by cell transfection with PL501 enhanced cell survival in both KJ29 (G) and Caki-2 (H) compared
with control cells. After transfection with either PL501 or irrelevant plasmid, cell survival was analyzed by CellTiter assay as described in method section. For KJ29 cells
cultured for 48 h, the values were 2.62 ± 0.09 in presence of PL501 and 2.49 ± 0.03 in presence of control plasmid (⁄⁄p < 0.01). After 72 h of culture, the absorbance values of
KJ29 cells treated with PL501 or control plasmid were 2.87 ± 0.08 and 2.65 ± 0.06, respectively (⁄⁄⁄p < 0.001). For Caki-2 cells cultured for 48 h, the values were 2.81 ± 0.03 in
presence of PL501 and 2.62 ± 0.05 in presence of control plasmid (⁄⁄⁄p < 0.001). For cells treated for 72 h with either PL501 or irrelevant plasmid, the values were 3.02 ± 0.11
and 2.75 ± 0.06, respectively (⁄⁄⁄p < 0.001). Reported data are represented as mean ± standard deviation (SD) from three independent experiments for the analysis of mTOR
activity and from three independent experiments in duplicate for the other ﬁndings in KJ29 cells, while data of Caki-2 cells were obtained from two different experiments in
duplicate.
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Fig. 3. The increased cell proliferation and survival in KJ29 and Caki-2 cells overexpressing miR501-5p is modulated by mTOR signaling in a mechanism involving MDM2 and
p53 proteins. (A and B) The overexpression of miR501-5p enhanced the levels of MDM2 protein (0.53 ± 0.12 in KJ29 control vs 1.32 ± 0.068 in KJ29 PL501-transfected cells,
⁄⁄⁄p < 0.001; 0.81 ± 0.16 in Caki-2 control vs 2.33 ± 0.47 in Caki-2 PL501-transfected cells, ⁄⁄⁄p < 0.001) and reduced the expression of p53 (1.62 ± 0.17 in KJ29 control cells vs
1.17 ± 0.10 in KJ29 PL501-transfected cells, ⁄p < 0.05; 0.95 ± 0.07 in Caki-2 control cells vs 0.58 ± 0.11 in Caki-2 PL501-transfected cells; ⁄⁄p < 0.01). Protein levels, analyzed by
western blot technique,were calculated as ratio between the band corresponding to the protein of interest and actin band, used as housekeeping gene for sample normalization.
(C) The overexpression of miR501-5p promoted the ubiquitination of p53 protein in KJ29 cells. After transfection with either PL501 (PL501) or control plasmid (C), cells were
treated with the proteasome inhibitor MG-132 (10 lm) for 4 h, lysed and part of protein solution was immunoprecipitated with an anti-p53 antibody. Next, cell lysates and
immunoprecipitated proteins were analyzed by western blotting using both anti-p53 and anti-Ubiquitin antibodies to detect p53 polyubiquitinated protein bands.
(IB = immunoblot; IP = immunoprecipitation). (D) The treatment with rapamycin enhanced p53 protein levels by reduction of both mTOR activity and MDM2 expression in
PL501-transfected KJ29 cells. Western blot analysis was carried out in KJ29 cells transfectedwith PL501 or control plasmid and treated for 24 h in presence (+) or absence () of
500 nM rapamycin. (E) The mTOR inhibitor rapamycin caused a decrease of cell proliferation in PL501-transfected KJ29 cells. Cells were transfected with PL501 (gray line) or
control plasmid (black line) and cultured in presence (dotted line) or absence (solid line) of 500 nM rapamycin for 24, 48 and 72 h in DMEM/F12medium supplementedwith 1%
FBS. As already observed in Fig. 2F, after 72 h of culture, PL501-transfected KJ29 cells grew more quickly than cells transfected with control plasmid (13,716 ± 542 cells vs
7822 ± 534 cells; ⁄⁄⁄p < 0.001). The treatment with rapamycin caused a signiﬁcant reduction of cell proliferation in KJ29 cells transfected with PL501 compared with untreated
cells (13,716 ± 542 for untreated cells vs 6055 ± 550 for rapamycin-treated cells; p < 0.001). (F and G) Cell survival, analyzed by CellTiter assay in cells cultured as described
above, is increased in both KJ29 and Caki-2 cells treatedwith PL501with respect to control cells (3.04 ± 0.078 for KJ29–PL501 vs 2.80 ± 0.076 for KJ29-control cells analyzed after
72 h of transfection, ⁄⁄⁄p < 0.001; 2.84 ± 0.05 for Caki-2-PL501 vs 2.68 ± 0.12 for Caki-2-control cells, transfected for 48 h, ⁄⁄p < 0.01; 2.97 ± 0.05 for Caki-2-PL501 vs 2.78 ± 0.08
for Caki-2-control cells, transfected for 72 h, ⁄⁄p < 0.01). Rapamycin treatment reduced cell survival compared with untreated cells (3.04 ± 0.078 for KJ29–PL501 untreated cells
vs 2.77 ± 0.04 for KJ29–PL501 cells treatedwith 500 nMrapamycin for 72 h, p < 0.001; 2.84 ± 0.05 for Caki-2-PL501 untreated cells vs 2.59 ± 0.08 for Caki-2-PL501 cells treated
with 500 nM rapamycin for 48 h, p < 0.01; 2.97 ± 0.05 for Caki-2-PL501 untreated cells vs 2.61 ± 0.03 for Caki-2-PL501 cells treated with 500 nM rapamycin for 72 h,
p < 0.001). Data are reported as mean ± standard deviation (SD) from three independent experiments for the analysis of MDM2 and p53 protein levels and from three
independent experiments in duplicate for cell growth and survival measurements in KJ29 cells, while data for Caki-2 cells were obtained from two different experiments in
duplicate.
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Fig. 4. MicroRNA501-5p downregulation reduced cell survival and promoted apoptosis by cell accumulation in G0/G1 phase of cell cycle and caspase-3 activation. (A) Real
Time RT-PCR analysis showed a reduction of about 50% in miR501-5p sequences in both KJ29 and Caki-2 cells transfected for 24 h with a speciﬁc antagomiR at 30 nM
concentration, that is the optimal molarity suggested by the manufacturer’s protocol. Data were expressed as ratio among cells transfected with antagomiR (A) and cells
treated with scramble sequences (S) calculated by delta-delta Ct method (0.47 ± 0.03-fold decrease; ⁄⁄⁄p < 0.001 for KJ29 cells and 0.57 ± 0.05-fold decrease; ⁄⁄⁄p < 0.001 for
Caki-2 cells). (B and C) Cell survival was inhibited in KJ29 and Caki-2 cells transfected with an antagomiR speciﬁc for miR501-5p (gray line) compared with control cells (black
line). Cells, transfected for 24 and 48 h with antagomiR or scramble sequences, were analyzed by CellTiter assay. Values after 48 h of transfection were 1.81 ± 0.077 and
2.31 ± 0.17 for KJ29 cells treated with antagomiR and scramble oligonucleotides, respectively (⁄⁄⁄p < 0.001), while for Caki-2 cells values were 3.02 ± 0.10 in cells treated with
scramble sequences and 2.81 ± 0.09 in antagomiR transfected cells (⁄p < 0.05). (D) Cell cycle analysis showed a signiﬁcant increase of G0/G1 phase in KJ29 cells treated with
antagomiR compared with control cells. After transfection, cells were cultured for 24 h in DMEM/F12 supplemented with 0.4% BSA, resuspended in propidium iodide and
analyzed by ﬂow cytometry. Cell percentage in G0/G1 phase was 67.5 ± 2.5% for KJ29-antagomiR cells and 60.5 ± 1.7% for KJ29-scamble cells (⁄⁄p < 0.01). Cell percentage in S
phase was 11 ± 2.2% for KJ29-antagomiR cells and 17.5 ± 3.1% for KJ29-scramble cells (⁄p < 0.05). (E) KJ29 cells transfected with the antagomiR showed higher caspase-3
activation than control cells (1027 ± 155 in cells treated with antagomiR vs 612 ± 41 in cells transfected with scramble sequences; ⁄⁄p < 0.01). After transfection with either
antagomiR or random sequences for 24 h, cells were collected, lysed and analyzed for caspase-3 activity by the EnzChek caspase-3 assay using a ﬂuorimeter for data
acquisition. Data are expressed as mean ± standard deviation from three different experiments in duplicate for Real time PCR and CellTiter analysis in KJ29 cells, and from two
different experiments in duplicate for cell cycle, caspase-3 assays and for ﬁndings achieved by Caki-2 cells.
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ligase and proteasome activator [30], caused the degradation of
p53 by protein polyubiquitination in miR501-5p-overexpressing
KJ29 cells (Fig. 3C). Finally, the reduction of mTOR activity by rap-
amycin treatment in miR501-5p-overexpressing KJ29 cells,
through the inhibition of MDM2 expression, restored the levels
of p53 protein (Fig. 3D). Therefore, mTOR kinase may negatively
modulate p53 protein expression in kidney carcinoma cells. Thisis also supported by the observation that downregulation of
miR501-5p in two different renal carcinoma cell lines (KJ29 and
Caki-2) increased the expression of p53 (Fig. 6A and B). Consis-
tently, the reduction of microRNA501-5p expression in KJ29 cells
treated with antagomiR, also induced a marked nuclear transloca-
tion of p53 (Fig. 6C), which were associated to the reduction of
mTOR activity (Fig. 5B) as well as MDM2 protein levels (Fig. 5C).
The enhanced activity of p53 tumor suppressor protein triggers
Fig. 5. The downregulation of miR501-5p induced apoptosis, reduction of mTOR activity and decreased the expression of MDM2 protein. (A) The analysis of apoptosis by
Hoechst method showed an increased number of apoptotic nuclei in KJ29 cells treated with the antagomiR as compared to control cells. KJ29 cells, seeded on coverslips, were
transfected with either antagomiR or scramble sequences in DMEM/F12 medium containing 0.4% BSA for 24 h. Next, cells were ﬁxed, permeabilized and stained with Hoechst
solution. Images were acquired by a ﬂuorescence microscope equipped with a CCD camera at 40magniﬁcation. Arrows in the squares indicated the apoptotic nuclei. (B) The
reduction of miR501-5p expression decreased the activity of mTOR kinase in KJ29 and Caki-2 cells. Values of mTOR activity were 0.52 ± 0.044 in KJ29 cells transfected with
scramble sequences and 0.37 ± 0.032 in KJ29 cells treated with antagomiR (⁄⁄p < 0.01); for Caki-2 cells values were 0.41 ± 0.11 in scramble cells and 0.225 ± 0.03 in cells
transfected with antagomiR (⁄p < 0.05). (C) MicroRNA501-5p downregulation reduced the expression of MDM2 protein in both KJ29 and Caki-2 kidney carcinoma cells. Values
for MDM2 expression were 0.15 ± 0.02 in KJ29 scramble transfected cells and 0.08 ± 0.01 in KJ29 cells treated with antagomiR (⁄⁄p < 0.01); for Caki-2 cells values were
2.12 ± 0.53 in scramble cells and 0.73 ± 0.10 in cells treated with antagomiR (⁄⁄p < 0.01). The activity of mTOR kinase and MDM2 expression, analyzed by western blotting in
KJ29 and Caki-2 cells transfected for 24 h with either antagomiR (A) or scramble sequences (S) was calculated as described in Fig. 2Dand E and Fig. 3A and B, respectively. Data
are represented as mean ± standard deviation (SD) from three independent experiments for KJ29 cells and from two different experiments in duplicate for Caki-2 cells.
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also through the formation of apoptotic nuclei (Figs. 4E and 5A). It
is interesting to note that the downregulation of miR501-5p may
also stimulate the activation of apoptosis by enhancing caspase-
1, 2 and 8 activity, being these proteases target of this miR
(Table 2). Since caspase-2 is also able to mediate the cleavage of
MDM2 [27], a greater activation of this enzyme through the
miR501-5p reduction would cause an increased MDM2 degrada-
tion with a more powerful activation of p53. Thus, the activationor inhibition of p53 in kidney carcinoma cells seems to be driven
by the expression of miR501-5p through the sequential modula-
tion of mTOR activity and MDM2 expression.
The relationship between expression of miR501-5p, mTOR
pathway and p53 modulation observed in vitro is supported by
studies on ccRCC tissues. In fact, ccRCC tissues with expression lev-
els of miR501-5p lower than the paired normal kidney paren-
chyma (<1) exhibited increased levels of p53, reduced mTOR
activity and decreased expression of MDM2 (Fig. 7A and B). This
Fig. 6. The reduction of miR501-5p enhanced both expression and function of tumor suppressor p53. (A and B) KJ29 and Caki-2 cells transfected with the antagomiR (A)
showed higher expression of p53 protein than cells treated with scramble sequences (S). Values were: 0.255 ± 0.08 for KJ29 control cells and 0.789 ± 0.07 for the same cells
transfected with antagomiR (⁄⁄p < 0.01). For Caki-2 cells values were 1.5 ± 0.70 for control cells and 3.66 ± 0.47 for cells transfected with the antagomiR (⁄⁄p < 0.01). Protein
levels were calculated as described in Fig. 3A and B. (C) The analysis of p53 by immunoﬂuorescence in KJ29-antagomiR cells highlight a greater nuclear translocation of p53
than in KJ29 control cells. Cells, seeded on 10 mm coverslips and transfected with either antagomiR or random sequences, were ﬁxed, permeabilized and treated with an anti-
p53 monoclonal antibody. After several washes, cells were treated with a secondary antibody conjugated with rhodamine. Nuclei were marked with Dapi and images were
acquired at 40magniﬁcation by a ﬂuorescence microscope equipped with a CCD camera. Arrows show the immunopositive nuclei. Data are represented as mean ± standard
deviation (SD) from three independent experiments in KJ29 cells and from two different experiments in duplicate for Caki-2 cells.
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in ccRCC patients with low levels of miR501-5p. However, as
shown in Fig. 7A (right part), 7B and 7C, the upregulation of this
miR in ccRCC tissues not always affected mTOR activity neither
the expression of MDM2 and p53 proteins. Nevertheless, this ﬁnd-
ing could be consistent with the lower informativeness on progno-
sis prediction observed in patients with high levels of this miRNA,
the most of which, anyway, may develop metastases (Table 1 and
Fig. 1F). Thus, differently from ‘‘in vitro’’ models, in ccRCC tissues
with higher expression of microRNA501-5p other mechanisms
able to modulate mTOR signaling could be involved. It is possible
that in these tissues, which are not protected by apoptosis any-
more, the disease may adversely progress in case of somaticmutations that activate oncogenic signals or inhibit tumor sup-
pressor proteins. In these patients, other biomarkers such as p53
expression should be taken into account because the role of this
tumor suppressor protein in advanced kidney carcinoma is cur-
rently discussed, being often associated with a poor prognosis
[40]. In fact, in some advanced ccRCC tissues a tremendous overex-
pression of p53 oncosuppressor protein was shown (samples iden-
tiﬁed by asterisk in Fig. 7C). But, differently from other cancers, few
somatic p53 mutations in ccRCC were reported [36], suggesting
that the inactivation of p53 might be due to other factors. Actually,
in metastatic ccRCC tissues the overexpression of p53 is associated
with an increased level of MDM2 protein that should induce p53
degradation [36,25]. Also the present ﬁndings show that advanced
Fig. 7. Analysis of mTOR activity, p53 and MDM2 protein expression in clear cell renal cell carcinoma tissues (ccRCC). (A) Western blot analysis of mTOR, MDM2 and p53
proteins in normal kidney parenchyma (N) and non-metastatic ccRCC tissues (T) expressing variable levels of microRNA501-5p. (B) Bars indicating western blot analysis
values of different kidney sample tissues (10 normal and 10 paired non-metastatic ccRCC) showed increased p53 expression, reduction of mTOR activity and decreased
MDM2 protein levels in ccRCC with low expression of miR501-5p (<1) compared with normal kidney tissues (values calculated as intensity band ratio between ccRCC and
normal kidney were: 2.67 ± 0.9-fold change for p53 protein levels, ⁄⁄⁄p < 0.001; 0.71 ± 0.34-fold change for MDM2 expression, ⁄p < 0.05; 0.53 ± 0.27-fold change for mTOR
activity, ⁄⁄⁄p < 0.001). No signiﬁcant changes were observed in 11 ccRCC which express greater levels of miR501-5p (>1) compared with 11 matched normal tissues. (C)
Western blot analysis of mTOR, MDM2 and p53 proteins in normal kidney parenchyma (N) and metastatic ccRCC tissues (T) which, usually, expressed unchanged or higher
levels of miR501-5p. Tumor samples with the higher expression of p53 protein were marked by the asterisk. (D) No signiﬁcant changes of p53 expression in 15 metastatic
ccRCC tissues compared with 15 paired normal kidney parenchyma samples were shown. (E) The activity of mTOR as well as the expression of MDM2 in metastatic ccRCC
tissues expressing high levels of p53 was greater than those with unchanged expression of p53. Values for MDM2 were: 8.36 ± 4.08-fold change in 7 ccRCC with p53 > 1 vs
1.46 ± 0.86 in 8 ccRCC with p53 6 1 (⁄⁄⁄p < 0.001); for mTOR activity were: 4.16 ± 1.88-fold change in 7 ccRCC with p53 > 1 vs 1.46 ± 0.29 in 8 ccRCC with p53 6 1 (⁄⁄p < 0.01).
The activity of mTOR and the levels of MDM2 and p53 proteins were calculated as described in Fig. 2D and Fig. 3A. Data are expressed as fold change ratio between normal
and ccRCC tissue.
Fig. 8. miR501-5p functions as a balance in the modulation of cell survival and apoptosis in clear cell renal carcinoma. The overexpression of miR501-5p promoted cell
growth and survival by activation of mTOR signaling. The reduction of miR501-5p expression caused the activation of the apoptotic pathway by p53 activation and mTOR
inhibition.
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well as mTOR phosphorylation compared with ccRCC tissues with
lower or unchanged p53 expression (samples marked with asterisk
in Fig. 7C and E). The enhancement of mTOR signaling may be asso-
ciated with unfavorable progression of kidney cancer [28] and, the
treatment with mTOR inhibitors might improve the survival in
patients with metastatic kidney carcinoma [6,15], as also observed
in our data (Fig. 3C–E). Therefore, as suggested in other studies,
these factors could be considered as candidate biomarkers useful
to detect poor prognosis for ccRCC patients [40,28,25].
In conclusion, we can speculate that miR501-5p may have a role
of balance among apoptosis and cell survival in kidney cancer cells
(Fig. 8). If expressed at low levels, miR501-5p could be considered
a new biomarker associated with good prognosis for ccRCC, just
because the expression of MDM2 remains low while p53 expres-
sion and apoptosis are stimulated. Conversely, the overexpression
of this miR caused cell growth and survival that could expose
ccRCC patients to development of metastasis and its informative-
ness on tumor prognosis becomes inaccurate. In this case, other
markers, like mTOR-associated elements which are involved in
advanced ccRCC, should be taken in account as important tool for
poor prognosis detection in ccRCC patients. Finally, the ﬁndings
here reported suggest that ccRCC patients who express high levels
of miR501-5p could be treated with speciﬁc miR501-5p antago-
nists as new therapeutic approach for the treatment of ccRCC.
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